enGenes Biotech, represented by by CEO Juergen Mairhofer, will attend the event at the City Cube Berlin Conference Center. enGenes will use the meeting to highlight their latest technologies and the company’s newly designed service portfolio, designed and structured on modular lines to provide a wide range of realistic options for companies looking to develop cost-effective manufacturing processes for recombinant proteins.
X-press applications
“We have attended every BIO-Europe conference since 2014 and find this is an excellent platform for widening and deepening our partnerships within the life sciences community,” said Dr. Mairhofer.
“We look forward to this opportunity to meet existing and potential new clients and to discuss exciting new opportunities to apply our enGenes-X-press technology to protein production and development,” he added.
The new enGenes service model is focused on the expression of difficult-to-express proteins covering all specific demands along the line from gene to protein., is divided into a series of steps that can be performed either individually or in combination – allowing customers to choose from a menu of the steps actually require, from cloning and vector optimization through to final purification.
Powerful production processes
The protein expression and production elements are enhanced by the power of the world-leading enGenes-X-press technology for growth-decoupled protein production in Escherichia coli (E.coli). This has allowed enGenes to develop economic, scalable and efficient production processes within short time frames.
“We are inviting anyone looking for flexible recombinant protein development and production solutions to contact us via BIO-Europe’s excellent partneringONE platform so we can set up face-to-face meetings in Berlin,” said Dr. Mairhofer.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
About BIO-Europe 2017
The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.
BIO-Europe 2017 is a three-day event opening November 6 at Berlin’s City Cube conference center.
BIO-Europe has formed the launch pad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.
This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.
Partnering at BIO-Europe 2017 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.
More information at: www.ebdgroup.knect365.com/bioeurope/
Press contact
enGenes Biotech
Dr. Juergen Mairhofer
CEO
Tel: +43 1 93 46 707
Email: office(at)engenes.cc